JP2026021299A5 - - Google Patents
Info
- Publication number
- JP2026021299A5 JP2026021299A5 JP2025159746A JP2025159746A JP2026021299A5 JP 2026021299 A5 JP2026021299 A5 JP 2026021299A5 JP 2025159746 A JP2025159746 A JP 2025159746A JP 2025159746 A JP2025159746 A JP 2025159746A JP 2026021299 A5 JP2026021299 A5 JP 2026021299A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- cell
- tcr
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475329P | 2017-03-23 | 2017-03-23 | |
| DE102017106305.6 | 2017-03-23 | ||
| DE102017106305.6A DE102017106305A1 (de) | 2017-03-23 | 2017-03-23 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| US62/475,329 | 2017-03-23 | ||
| JP2019552175A JP2020511152A (ja) | 2017-03-23 | 2018-03-23 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
| JP2023044130A JP7787119B2 (ja) | 2017-03-23 | 2023-03-20 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023044130A Division JP7787119B2 (ja) | 2017-03-23 | 2023-03-20 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026021299A JP2026021299A (ja) | 2026-02-10 |
| JP2026021299A5 true JP2026021299A5 (enExample) | 2026-03-11 |
Family
ID=61899213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552175A Withdrawn JP2020511152A (ja) | 2017-03-23 | 2018-03-23 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
| JP2023044130A Active JP7787119B2 (ja) | 2017-03-23 | 2023-03-20 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
| JP2025159746A Pending JP2026021299A (ja) | 2017-03-23 | 2025-09-26 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552175A Withdrawn JP2020511152A (ja) | 2017-03-23 | 2018-03-23 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
| JP2023044130A Active JP7787119B2 (ja) | 2017-03-23 | 2023-03-20 | Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法 |
Country Status (31)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| SG11202004116QA (en) | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| CN114026116A (zh) * | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| MA55903A (fr) * | 2019-05-08 | 2022-03-16 | Janssen Biotech Inc | Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| US20220401484A1 (en) * | 2019-11-18 | 2022-12-22 | BioNTech SE | Prame TCR Receptors And Uses Thereof |
| EP4093753A1 (en) * | 2020-01-24 | 2022-11-30 | Regeneron Pharmaceuticals, Inc. | Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof |
| CA3168729A1 (en) | 2020-02-24 | 2021-09-02 | Melinda MATA | Methods for expanding t cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022017435A1 (zh) * | 2020-07-22 | 2022-01-27 | 信达生物制药(苏州)有限公司 | 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用 |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| TW202241938A (zh) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Ｃｄ８多肽、組合物及其使用方法 |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| JP2024525727A (ja) | 2021-07-14 | 2024-07-12 | ２セブンティ バイオ インコーポレイテッド | 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230190806A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of treating metastatic lesions and compositions thereof |
| CN113817044B (zh) * | 2021-10-14 | 2023-10-13 | 深圳大学总医院 | T细胞受体、相关工程化细胞及其应用 |
| CN113789304B (zh) * | 2021-10-14 | 2023-03-31 | 深圳大学总医院 | 高亲和力tcr及其应用 |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| CA3255500A1 (en) | 2022-04-08 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | MULTI-PART RECEIVERS AND SIGNALING COMPLEXES |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4514829A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115073584B (zh) * | 2022-05-07 | 2023-10-20 | 溧阳瑅赛生物医药有限公司 | 一种特异性识别prame抗原肽的tcr及其应用 |
| CN117946246B (zh) * | 2023-02-23 | 2024-08-06 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025096983A1 (en) * | 2023-11-02 | 2025-05-08 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| CA2839663A1 (en) | 2011-06-28 | 2013-01-03 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific t cell |
| RU2578009C2 (ru) | 2013-05-08 | 2016-03-20 | Закрытое акционерное общество "ЕВРОГЕН" | Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках |
| KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
| CA2978171A1 (en) | 2015-03-10 | 2016-09-15 | J.H. Frederik Falkenburg | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
| EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| TW201702272A (zh) | 2015-05-22 | 2017-01-16 | 美國紀念斯隆 凱特琳癌症中心 | Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體 |
| CN106084036A (zh) | 2015-11-02 | 2016-11-09 | 广州市香雪制药股份有限公司 | 识别prame抗原短肽的t细胞受体 |
| CN106478809B (zh) | 2015-11-06 | 2018-06-01 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的tcr |
| CN106519019B (zh) | 2015-11-06 | 2018-07-03 | 广东香雪精准医疗技术有限公司 | 识别prame抗原的tcr |
| CN106831978B (zh) | 2015-12-04 | 2020-05-26 | 中国科学院广州生物医药与健康研究院 | 识别prame抗原的t细胞受体 |
| CN106699874B (zh) | 2016-03-29 | 2018-06-05 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的t细胞受体 |
| KR102436129B1 (ko) | 2016-06-17 | 2022-08-26 | 메디진 이뮤노테라피스 게엠바하 | T 세포 수용체 및 이의 용도 |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| DE102017106305A1 (de) * | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
-
2018
- 2018-03-22 US US15/928,785 patent/US11236145B2/en active Active
- 2018-03-23 SI SI201831150T patent/SI3600409T1/sl unknown
- 2018-03-23 ES ES18715559T patent/ES2986840T3/es active Active
- 2018-03-23 AU AU2018240501A patent/AU2018240501B2/en active Active
- 2018-03-23 MD MDE20200121T patent/MD3600409T2/ro unknown
- 2018-03-23 TW TW110126772A patent/TWI799922B/zh active
- 2018-03-23 MX MX2019011260A patent/MX2019011260A/es unknown
- 2018-03-23 CA CA3056493A patent/CA3056493A1/en active Pending
- 2018-03-23 RS RS20240992A patent/RS65924B1/sr unknown
- 2018-03-23 HU HUE18715559A patent/HUE068640T2/hu unknown
- 2018-03-23 PE PE2019001902A patent/PE20191493A1/es unknown
- 2018-03-23 KR KR1020197030006A patent/KR20190132655A/ko not_active Ceased
- 2018-03-23 CN CN201880019206.5A patent/CN110494160B/zh active Active
- 2018-03-23 SG SG11201908023Y patent/SG11201908023YA/en unknown
- 2018-03-23 IL IL310552A patent/IL310552B2/en unknown
- 2018-03-23 CR CR20190482A patent/CR20190482A/es unknown
- 2018-03-23 PL PL18715559.3T patent/PL3600409T3/pl unknown
- 2018-03-23 EP EP24194122.8A patent/EP4450087A3/en active Pending
- 2018-03-23 SM SM20240351T patent/SMT202400351T1/it unknown
- 2018-03-23 MY MYPI2019005257A patent/MY199084A/en unknown
- 2018-03-23 BR BR112019019523-8A patent/BR112019019523A2/pt unknown
- 2018-03-23 IL IL269578A patent/IL269578B2/en unknown
- 2018-03-23 DK DK18715559.3T patent/DK3600409T3/da active
- 2018-03-23 PT PT187155593T patent/PT3600409T/pt unknown
- 2018-03-23 JP JP2019552175A patent/JP2020511152A/ja not_active Withdrawn
- 2018-03-23 LT LTEPPCT/EP2018/057482T patent/LT3600409T/lt unknown
- 2018-03-23 HR HRP20241228TT patent/HRP20241228T1/hr unknown
- 2018-03-23 CN CN202410804111.1A patent/CN118852404A/zh active Pending
- 2018-03-23 EP EP18715559.3A patent/EP3600409B1/en active Active
- 2018-03-23 MA MA47932A patent/MA47932B1/fr unknown
- 2018-03-23 KR KR1020247033132A patent/KR20240151870A/ko active Pending
- 2018-03-23 FI FIEP18715559.3T patent/FI3600409T3/fi active
-
2019
- 2019-09-16 CL CL2019002645A patent/CL2019002645A1/es unknown
- 2019-09-19 PH PH12019502151A patent/PH12019502151A1/en unknown
- 2019-09-20 MX MX2023003463A patent/MX2023003463A/es unknown
- 2019-10-22 CO CONC2019/0011688A patent/CO2019011688A2/es unknown
-
2021
- 2021-12-16 US US17/553,017 patent/US20220098270A1/en active Pending
-
2023
- 2023-03-20 JP JP2023044130A patent/JP7787119B2/ja active Active
-
2025
- 2025-03-24 AU AU2025202086A patent/AU2025202086A1/en active Pending
- 2025-09-26 JP JP2025159746A patent/JP2026021299A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026021299A5 (enExample) | ||
| JP2019528061A5 (enExample) | ||
| ES2565481T3 (es) | Anticuerpo anti-PlGF novedoso | |
| ES2374845T3 (es) | Tratamiento de cáncer con anticuerpos anti-il-1. | |
| JP2019511222A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| JP6070191B2 (ja) | 癌の治療及び／又は予防用医薬組成物 | |
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2019536430A5 (enExample) | ||
| ES2373652T9 (es) | Anticuerpo citotóxico contra un péptido C-terminal de GPC-3 | |
| CN103717238A (zh) | 胰癌的治疗和/或预防用药物组合物 | |
| JP2023512039A5 (enExample) | ||
| JP2016505513A5 (enExample) | ||
| JP2020513745A5 (enExample) | ||
| JP2019534246A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| RU2020127887A (ru) | Полипептиды транспозазы и их применение | |
| CN110272490A (zh) | 靶向ctla-4抗体、其制备方法和用途 | |
| JP2024531409A5 (enExample) | ||
| HUP0401695A2 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
| JP2021530971A5 (enExample) | ||
| KR20210143804A (ko) | 혈액암 및 고형 종양암의 치료를 위한 키메라 항원 수용체 변형된 t 세포 (car-t) | |
| JP2023089103A5 (enExample) | ||
| JP2024508808A5 (enExample) | ||
| CA2917584C (en) | Genetically stable oncolytic rna virus, method of manufacturing and use thereof |